TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04475705
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
Study: NCT04475705
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
Study: NCT06333600
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic intervention
Study: NCT06333600
Drug: Topical Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic intervention
Study: NCT05814627
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT05814627
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT05814627
Drug: Upadacitinib Matching Placebo
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT05814627
Drug: Adalimumab Matching Placebo
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT05580445
Drug: CT-707
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal Adhesion Kinase (FAK) inhibitor
Study: NCT05580445
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed Death 1(PD-1) antibody
Study: NCT05580445
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: nucleoside inhibitor
Study: NCT04961580
Drug: Ceftazidime Avitbatan Sodium
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
Study: NCT05963022
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06580041
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAU plan modified to include a trial of pramipexole.
Study: NCT06580041
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
Study: NCT06580041
Drug: Phenelzine
Normalized name: Phenelzine
DrugBank: Phenelzine (DB00780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
Study: NCT04387227
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02715843
Drug: MT-3724
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
Study: NCT05692570
Drug: PBI-200 Tablet
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBI-200 is a TRK inhibitor
Study: NCT05692570
Drug: Ritonavir Oral Tablet
Normalized name: ritonavir Oral Tablet
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir is a potent CYP3A inhibitor
Study: NCT05692570
Drug: Cobicistat Oral Tablet
Normalized name: cobicistat Oral Tablet
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cobicistat is a potent CYP3A inhibitor
Study: NCT04349826
Drug: Cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefixime 20-30 mg/kg/day for 7 days
Study: NCT05243693
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of Brentuximab vedotin and DHAP
Study: NCT06092268
Drug: SHR-A2009 for injection ； Almonertinib Mesilate Tablets
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase IB: SHR-A2009 will be administered intravenously，Almonertinib Mesilate Tablets will be administered orally. 2 or 3 dose levels are preset in phase IB.~Phase II: 2 dose cohorts will be selected and it's randomization.
Study: NCT06092268
Drug: SHR-A2009 for injection；Adebrelimab Injection
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase IB: SHR-A2009 and Adebrelimab will be administered intravenously. 2 dose levels are preset in phase IB.~Phase II: RPD2 will be selected to evaluate preliminary efficacy.
Study: NCT05625555
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketamine infusion 0.5mg/kg over 40 minutes
Study: NCT05625555
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Midazolam infusion 30μg/kg over 40 minutes
Study: NCT05163249
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study: NCT05163249
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
Study: NCT03909594
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine
Study: NCT03909594
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine
Study: NCT06415500
Drug: NK042
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NK042 intraperitoneal infusion on Days 0,7 and 14.
Study: NCT05155189
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tyrosine kinase inhibitors
Study: NCT05155189
Drug: PD-1(L1) monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors, ICIs
Study: NCT05569590
Drug: Propolis
Normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vital tooth bleaching will be performed and Propolis as a desensitizing agent will be applied after bleaching to reduce dentine hypersensitivity.
Study: NCT05569590
Drug: hydrogen peroxide 35%
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrogen peroxide 35%
Study: NCT05928546
Drug: Quercetin
Normalized name: Quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-pocket application of quercetin nanoemulgel :~* After conventional periodontal treatment, the teeth were isolated by cotton rolls for intra pocket application of the gel.~* That gel was injected in periodontal pocket using syringe with blunt cannula till the gel excess exit from the pocket .
Study: NCT00000776
Drug: Flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000776
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000776
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000776
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04801056
Drug: TB006
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TB006 monoclonal antibody
Study: NCT00037089
Drug: UFT (Tegafur/Uracil)
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05861986
Drug: risdiplam
Normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Study: NCT00000705
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06312475
Drug: KN057
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KN057 will be administered subcutaneously once a week.
Study: NCT06054750
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
Study: NCT04896697
Drug: vilastobart (XTX101)
Normalized name: Vilastobart
DrugBank: Vilastobart (DB19327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vilastobart (XTX101) monotherapy
Study: NCT04896697
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
Study: NCT04896697
Drug: vilastobart (XTX101)
Normalized name: Vilastobart
DrugBank: Vilastobart (DB19327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In combination with Atezolizumab
Study: NCT05492877
Drug: Mitiperstat (AZD4831)
Normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage, once daily.
Study: NCT05855967
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT06652165
Drug: zanubrutinib combined with BEAM
Normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Study: NCT06652165
Drug: BEAM
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
Study: NCT06653699
Drug: 2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
Study: NCT06653699
Drug: 1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
Study: NCT05107752
Drug: Stellate Ganglion Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
Study: NCT05069870
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole, capsule, oral
Study: NCT05069870
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil, capsule, oral
Study: NCT05069870
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin, capsule, oral
Study: NCT05199649
Drug: SintilimabCombined With Chemotherapy
Normalized name: Primatene with ephedrine Pill
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
Study: NCT06532240
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
Study: NCT06231771
Drug: Allogeneic mesenchymal stem cells (MSCs)
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
Study: NCT06103617
Drug: Penicillamine
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
Study: NCT05667077
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
Study: NCT05024968
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT06421103
Drug: Indocyanine Green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohorts will receive 0.01 mg/kg, 0.02 mg/kg, 0.04mg/kg, 0.06 mg/kg, or 0.08 mg/kg intra-venous ICG at surgery. Patients will be consecutively allocated to different doses as per protocol.
Study: NCT05779059
Drug: De-escalation to ticagrelor 60 mg at day 30
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
Study: NCT05977738
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily Pitavastatin administration
Study: NCT06153004
Drug: Antidepressant medication (ADM)
Normalized name: THP-Adm
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
Study: NCT05779059
Drug: De-escalation to prasugrel 5 mg at day 30
Normalized name: prasugrel 5 MG
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
Study: NCT05779059
Drug: Switch to ticagrelor 60 mg at day 45
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switch to ticagrelor 60 mg bid at day 45.
Study: NCT05779059
Drug: Switch to prasugrel 5 mg at day 45
Normalized name: prasugrel 5 MG
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch to prasugrel 5 mg qd at day 45.
Study: NCT05317780
Drug: rAAV9-CB6-AspA
Normalized name: rAAV9-rsATP7A
DrugBank: rAAV9-rsATP7A (DB17664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
Study: NCT00040560
Drug: 111In-DAC
Normalized name: DAC
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05867329
Drug: Cyclosporine Injection (IV)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers.
Study: NCT05867329
Drug: Cyclosporine Oral Product
Normalized name: cyclosporine Oral Product
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician.
Study: NCT05867329
Drug: Upadacitinib Extended Release Oral Tablet
Normalized name: upadacitinib Extended Release Oral Tablet
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital.
Study: NCT05867329
Drug: Prednisone Oral Product
Normalized name: prednisone Oral Product
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Study: NCT06084780
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
Study: NCT06084780
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
Study: NCT06084780
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
Study: NCT05562882
Drug: Daratumumab Injection
Normalized name: daratumumab Injection
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous daratumumab administration
Study: NCT06261814
Drug: Sulfur Hexafluoride Lipid Microspheres
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05171062
Drug: bexmarilimab (FP-1305)
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Bexmarilimab (DB16383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
Study: NCT05171062
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
Study: NCT04497038
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
Study: NCT00000722
Drug: Pentamidine isethionate
Normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no